Enliven Therapeutics (ELVN) Stock Forecast & Price Target

ELVN$48.80+0.49 +1.01%
BiotechnologyGrowth Stock
Compare
Market cap$3.59BEnterprise value$3.62BRevenue (TTM)$0Market position—

Score

68
Bullish
Value
58
Quality
47
Growth
100

Enliven Therapeutics, Inc. price target

ELVN
Low$70.00
Average$76.29
High$82.00
Upside vs current price+56.3%

The average target of $76.29 is +56.3% versus the current ELVN price of $48.80.

Enliven Therapeutics, Inc. analyst ratings

RatingAnalysts
Strong buy3
Buy11
Hold0
Sell0
Strong sell0
ConsensusBuy

14 analysts cover ELVN.

Enliven Therapeutics, Inc. EPS and revenue estimates

ELVN shows the next fiscal years with at least three analysts: 2026 EPS $-1.86, 2027 EPS $-2.27. A thinner year is left off this table.

Fiscal yearEPS estimateRevenue estimate
2026$-1.86$10,000
2027$-2.27$5,000

Is Enliven Therapeutics, Inc. a buy or sell?

Of the 14 analysts covering Enliven Therapeutics, Inc., 14 rate it a buy (3 strong buy and 11 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).

The ELVN consensus label is Buy, beside 14 buy-side ratings and 0 sell-side ratings.

The average target of $76.29 implies +56.3% versus the current price of $48.80.

Those 14 ratings on ELVN are a headcount, and the label on file is Buy.

Reading the Enliven Therapeutics, Inc. forecast

The ELVN targets sit in a narrow band, from $70.00 to $82.00, around an average of $76.29.

Set next to the $48.80 ELVN quote, that average is +56.3%.

Ratings on the Enliven Therapeutics, Inc. cluster: 14 of 14 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.

The average ELVN target over the last month is $73.00, below the $76.29 quarterly average.

Only 14 analysts cover ELVN, so the average rests on a short list.

Enliven Therapeutics, Inc. forecast questions

What is the ELVN price target?

The published range for ELVN is $70.00 to $82.00, with an average of $76.29. That average is +56.3% versus the current price of $48.80.

Is Enliven Therapeutics, Inc. a buy or sell?

Of the 14 analysts covering Enliven Therapeutics, Inc., 14 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the ELVN headcount is 14 buy, 0 hold, and 0 sell.

What is the EPS estimate for Enliven Therapeutics, Inc.?

Analyst EPS estimates for Enliven Therapeutics, Inc.: 2026 $-1.86, 2027 $-2.27.

What is the revenue estimate for Enliven Therapeutics, Inc.?

Analyst revenue estimates for Enliven Therapeutics, Inc.: 2026 $10,000, 2027 $5,000.

How many analysts cover ELVN?

14 analysts cover ELVN. Their consensus on ELVN is Buy, across those 14.

ELVN price $48.80 +0.49 +1.01%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener